Snipd home pageGet the app
public
The HemOnc Pulse chevron_right

What Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?

Mar 23, 2023
27:10
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 3min
chevron_right
2
The Cost Effectiveness of a Novel Therapy for Lymphoma
02:32 • 2min
chevron_right
3
Cost Effectiveness in Hematology
04:36 • 2min
chevron_right
4
The Cost-Effectiveness of Polar to Zuma in the Front-Line Setting
06:56 • 2min
chevron_right
5
How to Design a Markov Model to Address Cost-Depactiveness
08:49 • 3min
chevron_right
6
How to Calculate the Quality of Life
11:31 • 3min
chevron_right
7
The Cost Effectiveness of Polar Hustle
14:22 • 2min
chevron_right
8
The Cost Effectiveness of Polar Chip
16:11 • 3min
chevron_right
9
The Cost Effectiveness of Polar Chips
18:46 • 3min
chevron_right
10
The Cost-Effectiveness of Imaging Studies
22:00 • 3min
chevron_right
11
The Cost-Effectiveness of a Chip Pulse
25:07 • 2min
chevron_right
Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously untreated DLBCL.
HomeTop podcastsPopular guests